Strides Pharma Science 公布 24 财年第四季度净利润为 1.044 亿卢比，创下有史以来最高的全年收入，并任命 Badree Komandur 为董事总经理兼首席执行官。 Strides Pharma Science reports Q4 FY24 net profit of Rs 10.44 crore, highest-ever full-year revenue, and appoints Badree Komandur as MD & CEO.
Strides Pharma Science Ltd 公布其 24 财年第四季度净利润为 1.044 亿卢比，高于去年同期的净亏损 1.379 亿卢比。 Strides Pharma Science Ltd reported a Q4 FY24 net profit of Rs 10.44 crore, up from a net loss of Rs 13.79 crore in the same period last year. 受美国和其他受监管市场增长的推动，该公司在 24 财年创下了有史以来最高的全年收入，实现综合总收入 4,090.82 千万卢比，高于 23 财年的 3,778.71 千万卢比。 The company recorded its highest-ever full-year revenue in FY24, driven by growth in the US and other regulated markets, achieving a consolidated total income of Rs 4,090.82 crore, up from Rs 3,778.71 crore in FY23. 现任首席财务官的 Badree Komandur 将于 2024 年 6 月 1 日起担任董事总经理兼首席执行官。 Badree Komandur, currently CFO, will serve as MD & CEO from June 1, 2024.